1 924
Subscribers
No data24 hours
+97 days
+4330 days
Data loading in progress...
Similar Channels
Tags Cloud
No data
Any problems? Please refresh the page or contact our support manager.
Incoming and Outgoing Mentions
---
---
---
---
---
---
Attracting Subscribers
December '24
December '24
+23
in 0 channels
November '24
+48
in 0 channels
Get PRO
October '24
+35
in 0 channels
Get PRO
September '24
+135
in 0 channels
Get PRO
August '24
+44
in 0 channels
Get PRO
July '24
+24
in 0 channels
Get PRO
June '24
+20
in 0 channels
Get PRO
May '24
+29
in 0 channels
Get PRO
April '24
+17
in 0 channels
Get PRO
March '24
+32
in 0 channels
Get PRO
February '24
+27
in 0 channels
Get PRO
January '24
+1 868
in 0 channels
| Date | Subscriber Growth | Mentions | Channels | |
| 21 December | 0 | |||
| 20 December | +1 | |||
| 19 December | +1 | |||
| 18 December | 0 | |||
| 17 December | +4 | |||
| 16 December | 0 | |||
| 15 December | +2 | |||
| 14 December | +2 | |||
| 13 December | +3 | |||
| 12 December | +2 | |||
| 11 December | 0 | |||
| 10 December | +2 | |||
| 09 December | +1 | |||
| 08 December | +1 | |||
| 07 December | 0 | |||
| 06 December | 0 | |||
| 05 December | 0 | |||
| 04 December | +1 | |||
| 03 December | 0 | |||
| 02 December | +3 | |||
| 01 December | 0 |
Channel Posts
| 2 | https://youtu.be/_CWMUt8Xi_Y?si=6qluSTG81CaGpMxP
Iron absorption | 671 |
| 3 | ASH 2023 Edu book.pdf | 492 |
| 4 | Hematology Board Review | 510 |
| 5 | Algorithm_for_the_initial_treatment_of_immune_thrombotic_thrombocytopenic.pdf | 559 |
| 6 |  Porphyria | 576 |
| 7 | Porphyria | 1 |
| 8 | +2 pseudo pelger huet neutrophils | 573 |
| 9 | +2 Babesiosis | 523 |
| 10 | Majeed syndrome is a rare condition in which patients will have recurrent episodes of fever and inflammation in the bones and skin. One of the major features of Majeed syndrome is an inflammatory bone condition known as chronic recurrent multifocal osteomyelitis (CRMO). This condition causes recurrent episodes of pain and joint swelling beginning in infancy or early childhood. These symptoms persist into adulthood, although they may improve for short periods of time. CRMO can lead to complications such as slow growth and the development of joint deformities (contractures), which restricts the movement of certain joints.
Another feature of Majeed syndrome is the development of a blood disorder, Congenital dyserythropoietic anemia.
Most patients with Majeed syndrome also develop inflammatory disorders of the skin, most often a condition known as Sweet syndrome. The symptoms of Sweet syndrome include fever and the development of painful bumps or blisters on the face, neck, back and arms.
It is inherited in an autosomal recessive manner. Majeed syndrome results from mutations in the LPIN2 gene. This gene provides instructions for making a protein called lipin-2. This protein may play a role in the processing of fats, controlling inflammation and in cell division.
The treatment for this disease is uncertain. However, reports suggests that for severe disease, IL-1β blockade has been reported to be highly effective at controlling osseous and systemic inflammation. MTX and bisphosphonates have also shown to be beneficial. | 596 |
| 11 | No text... | 467 |
| 12 | Treatment of acute acquired methemoglobinemia:
➡️A offending agent should be removed and/or discontinued.
The most commonly implicated agents include dapsone, local (topical) anesthetic agents, aniline dyes, and high nitrate levels in water supplies.
➡️In asymptomatic patients, usually those with methemoglobin levels <20 percent, no therapy other than discontinuation of the offending agent.
➡️If the patient is symptomatic does not have(G6PD) deficiency, use IV Methylene blue.
The usual dose in this setting is 1 to 2 mg/kg, given over five minutes.
➡️If a patient has G6PD deficiency, should be offered Ascorbic acid. | 516 |
| 13 | +3 Methemoglobinemia | 457 |
| 14 | Choice_of_thromboprophylaxis_in_patients_with_multiple_myeloma.pdf | 361 |
| 15 | Overview of the management of beta thalassemia.pdf | 635 |
| 16 | Disease-modifying therapies for sickle cell disease | 661 |
| 17 | PERC (Pulmonary Embolism Rule-out Criteria)
is used in the initial evaluation of patients to assess the likelihood of them having a pulmonary embolism (PE). It is specifically utilized in the evaluation of low-risk patients to exclude the diagnosis of a pulmonary embolism based on historical and physical examination data.
A patient’s overall risk status is first determined by either clinician judgement or by using the Wells Criteria. If a patient fails to meet any of the below criteria then a D-dimer can be done to aid in the decision of whether the patient should be sent to receive a CT Chest angiography to rule out the presence of a PE.
The PERC criteria includes:
- Age < 50 years
- Pulse < 100 bpm
- SaO2 > 94%
- No unilateral swelling
- No hemoptysis
- No recent trauma or surgery
- No prior PE or DVT
- No hormone use | 707 |
| 18 | MD Anderson board review 2023 is now available on P cloud
https://u.pcloud.link/publink/show?code=kZJTz70Z6I0RI9dlJWLuuFvEFWuLafcKVndk | 626 |
| 19 | Approach to treatment of pregnant and postpartum patients with APS or aPL
Antepartum Postpartum
APS with p | 834 |
| 20 |  Coagulation Cascade | 881 |
